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INTRODUCTION
Cutaneous melanoma is the most common type of 
melanoma and is responsible for the majority of deaths 
caused by skin malignancies. Th e incidence of this 
tumor is increasing worldwide, especially in the fair-
skinned populations (1). Early detection of melanoma 
is the best way to reduce mortality. Primary cutane-
ous melanoma may develop in precursor melanocytic 
nevi, arise de novo (stages I and II), or present with 
metastatic spread (stages III and IV). Surgery is the 
primary mode of therapy for localized cutaneous mel-
anoma (2). Aft er the surgery, many patients remain 
disease free for the rest of life, whereas others can have 
disease recurrence. Recurrence or progression can be 
in the form of locoregional and/or distant metastasis, 
which can be fatal. Th e recurrence rates are infl uenced 
by the stage at which the primary disease fi rst presents 
and by the treatment received. 
Important factors in the melanoma staging system are 
the presence of ulcerations and mitotic rates. Th ey are 
used to complement depth of invasion to assign the 
stage. Th e increasing mitotic rate among patients with 
clinically node-negative (cN0) primary melanoma 
was signifi cantly associated with decreasing melano-
ma-specifi c survival (MSS) on univariate analysis (3).
Most of the initial recurrences occur in the fi rst 2 years 
aft er the primary disease diagnosis. Initial recurrenc-
es 10 years aft er the initial treatment are termed late 
recurrences and those occurring aft er 15 years of dis-
ease-free interval are termed ultra-late recurrences (4).
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CASE REPORT
A 64 year-old man presented to a local hospital with a 
painless lymph node (2 cm) in the right supraclavic-
ular area. Th e node was slightly moveable under the 
skin. He reported a history of cutaneous malignant 
melanoma on his back excised 34 years before (Fig-
ure 1). His discharge summary documented radical 
excision of the skin, fat, deep fascia and split thickness 
skin graft  reconstruction, which confi rmed malignacy 
with no evidence for further spread. He recalled no 
adjuvant therapy or disease recurrence in the 34-year 
period. Breslow and Clark thickness was not available 
for our case as the primary diagnosis was set 34 years 
prior to the disease recurrence.
Fig. 1. Th e site of primary melanoma occurrence on the 
patient’s back aft er excision and reconstruction by rotation 
fl ap.
Neck ultrasound confi rmed an oval anechogenic/hy-
poechogenic lobular lesion (1.6x1.7 cm) in the right 
supraclavicular fossa. Fine-needle aspiration (FNA) 
sample of the solitary neck mass revealed sparse popu-
lation of the poorly preserved malignant cells and bare 
malignant nuclei with prominent nucleoli. Because of 
that, extirpation of that lymph node was recommend-
ed. Extirpation of the lymph node was done under en-
dotracheal anesthesia (ETA) and the histopathologic 
diagnosis confi rmed metastatic melanoma (Figures 2 
and 3). Th e man was referred to dermatologist, oph-
thalmologist and gastroenterologist for further man-
agement to exclude other potential sites of new prima-
ry melanoma. 
Fig. 2. Lymph node is infi ltrated with abundant tumor tissue 
composed of aggregates of spindle-shaped, atypical polygonal 
melanocytes.
Fig. 3. Tumor tissue is melan A and S100 positive.
In the following, rather short, period of 3 weeks, while 
the patient was preparing for the procedure of ‘radical 
right neck dissection’, clinical examination revealed 
three oval palpable masses under the postoperative 
incision. Neck computed tomography (CT) and ul-
trasound showed the presence of one clinically sus-
picious lymph node on the right, between the lateral 
side of the operative incision and the clavicle (6.6 mm) 
and two clinically suspicious lymph nodes above the 
middle part of the postoperative incision (4.8 mm and 
4.4 mm). Positron emission tomography/computed 
tomography (PET/CT) confi rmed two foci of patho-
logical metabolism (Figure 4).
Z. Kljajić, P. Smoje, P. Ivanišević, S. Ercegović, N. Kunac, K. Bečić, N. Puizina-Ivić
An incidental fi nding of nodal neck recurrence of cutaneous malignant melanoma aft er a 34-year disease-free period (na engl.)
Acta Med Croatica, 73 (2019) 199-203
201
Fig. 4. Preoperative PET/CT of the right supraclavicular 
region.
Radical right neck dissection was immediately per-
formed. Histology confi rmed three lymph nodes al-
most completely replaced by metastatic melanoma 
with no extracapsular spread (Figure 5). Th e oncologic 
team decided to administer radiotherapy to the right 
side of the neck and supraclavicular region in a dose of 
42 Gy in 7 fractions.
Fig. 5. Histologically, the three nodes of the fi ft h level are 
infi ltrated with tumor tissue composed of spindle atypical 
lymphocytes showing moderate pleomorphism. Th e capsule 
of the lymph node is intact.
No clinical signs of recurrence were noted on his post-
operative and post-radiotherapy outpatient visits. Fol-
low up neck and abdomen ultrasound and PET/CT at 
6 months were tumor-free (Figure 6). Th e patient is 
still alive and healthy, and has being regularly exam-
ined by the oncologist, dermatologist and otorhinola-
ryngologist, with no evidence for almost 5-years fol-
low-up period.
Fig. 6. Follow up PET/CT 6 months aft er the operation.
DISCUSSION
Th e patient described had no evidence for second 
cutaneous primary melanoma. Clinical examination, 
ultrasound and PET/CT examination showed no 
evidence for non-cutaneous melanoma. Th e nodal 
metastasis observed was in the draining basin appro-
priate for the original primary tumor to be the cause, 
which supports the theory that this case was a recur-
rence. It is therefore assumed that the metastasis was 
an ultra-late recurrence, 34 years following the origi-
nal melanoma.
Th e ultra-late recurrence of cutaneous melanoma 
with several decades of quiescence is extremely rare. 
We found the currently longest latency period of dis-
ease-free survival from diagnosis to recurrence to be 
45 years (5).
In our case, the patient was symptomatic, so the accu-
rate diagnosis was easily established and the right ther-
apy was applied in a rather short period from the fi rst 
doctor appointment. It is speculated that a number 
of patients may present with or die from widespread 
metastasis, never being brought to the attention of the 
doctors that originally treated them.
Malignant melanoma is a possible life threatening dis-
ease with development of regional or distant metasta-
ses. In most patients, metastases occur within the fi rst 
2 to 5 years aft er excision of the primary tumor. Th e 
majority of recurrences and deaths resulting from ma-
lignant melanoma can be seen within 5 years aft er the 
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treatment of the primary tumor. Late recurrences, de-
fi ned as those occurring 10 or more years aft er the di-
agnosis, are relatively uncommon events (6). Th ere are 
well-recognized prognostic factors infl uencing overall 
and disease-free survival following treatment with 
curative intent for primary melanoma. Th e strong-
est indicator of prognosis is Breslow thickness, which 
unfortunately was not available in our case as the pri-
mary diagnosis had been set 34 years prior to the dis-
ease recurrence (1). 
Number of tumor-involved regional nodes, one ver-
sus two or three versus four or more metastatic nodes, 
presence of in-transit/satellite/microsatellite disease, 
and sentinel node tumor burden are also negative 
prognostic factors. Other factors adversely aff ecting 
prognosis are ulceration status, mitotic rate, age old-
er than 65 years and male gender (7). Th ese negative 
prognostic features appear to be largely confi ned to 
patients having recurrences within 10 years of their 
primary diagnosis. Late progression of disease is rare; 
it is of high clinical interest to identify the risk of late 
metastases and possible risk factors to establish effi  -
cient long-term follow-up programs for patients with 
malignant melanoma. Schmid-Wendtner et al. found 
higher rates of late recurrence in men with primary 
tumors located on the trunk. In their study, survival 
aft er late recurrence did not correlate with disease-free 
survival (6). Faries et al. found late recurrence to be 
associated with both tumor (thin, non-ulcerated, non-
head/neck, node negative) and patient (younger age, 
less male predominant) characteristics. Multivariate 
analysis confi rmed younger age, thinner and node 
negative tumors in the late recurrence group. Late re-
currences were more likely to be distant, but were as-
sociated with better post-recurrence survival on uni-
variate and multivariate analyses (8). However, Tsao 
et al. concluded that ultra-late recurrences could oc-
cur in any patient without identifi able risk factors (9). 
Sella-Abate et al. analyzed 1372 melanoma patients 
disease free for more than 10 years. Seventy-seven of 
them progressed aft er this time point. Th e fi rst recur-
rence was regional in 52 and distant in 25 patients. 
Lymph node recurrence was most common among re-
gional recurrences. Distant recurrence was character-
ized by visceral involvement. Th e two most common 
single sites were brain and lung (10).
Melanoma is oft en considered to be a radio resistant 
tumor. However, some studies showed that adjuvant 
radiation therapy provided good regional control. 
Bibault et al. recommend using adjuvant radiation 
therapy for patients with lymph node metastases from 
cutaneous melanoma, especially if they present one 
or more lymph nodes with extracapsular extension 
(11). Th e total dose should be between 30 and 70 Gy, 
considering the region of radiation, with a standard 
fractionation regimen in order to maximize the effi  -
cacy and minimize toxicity (11). Our oncology team, 
considering the regions of radiation and complica-
tions which can occur, decided to administer radiation 
therapy in a total dose of 42 Gy.
Th ere are four types of cutaneous melanoma: superfi -
cial spreading, lentigo maligna, acral lentigonous and 
nodular. 
Feichtenschlager et al. found that superfi cial spreading 
melanoma (39.5%) was the most frequent histological 
subtype (12).
Survival analysis of a  sub-cohort of 577 patients 
showed better 5-year overall survival for women com-
pared to men (75.8% vs. 63.6%; p=0.025) irrespective 
of the type and stage of cutaneous melanoma (12).
Melanoma is an aggressive and highly metastatic dis-
ease. Over several decades, the incidence of melano-
ma has steadily risen, and the incidence rates have 
increased and continue to rise nowadays. Th e initial 
sites of distant metastases are most commonly the 
skin, subcutaneous tissue and lymph nodes. Th e most 
common sites of visceral metastases are the lung, 
brain, liver and bone. In patients with melanoma, 
metastatic disease is felt to be very unlikely if there 
has been no recurrence of disease for 10 years aft er 
initial treatment. However, such late recurrences are 
known to occur. Because of lifelong risk of melanoma 
recurrence, lifetime follow-up of melanoma patients 
is highly recommended. Education of patients, espe-
cially those with cutaneous melanoma, about qualifi ed 
self-examination for early detection of other primary 
melanomas is necessary. Th ey need to be followed up 
under the care of a hospital specialist, as advised by 
the UK guidelines for the management of cutaneous 
melanoma (13). In the end, we can only say that mela-
noma is a never-ending story.
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Prikazujemo slučaj 64-godišnjeg muškarca koji je imao metastazu melanoma u limfnom čvoru 34 godine nakon postav-
ljene dijagnoze kožnog melanoma na leđima. Na ultrazvuku je ponađena ovalna anehogena/hipoehogena lobularna lezija 
(1,6x1,7 cm) u desnoj supraklavikularnoj regiji. Citološka punkcija je ukazivala na slabo diferencirane maligne stanice. Uči-
njena je ekstirpacija limfnog čvora i patohistološki nalaz je potvrdio metastatski melanom. Daljnjom obradom (pozitronska 
emisijska tomografi ja, pregled dermatologa, oftalmologa i i gastroenterologa) nije pronađeno novo sijelo primarnog me-
lanoma. To je jedno od najdužih razdoblja između primarnog melanoma i povratka bolesti opisano do danas. Ovaj prikaz 
pokazuje da se metastaze melanoma mogu javiti tijekom cijelog života. Liječnici i bolesnici moraju biti svjesni rizika kasnih 
metastaza.
Ključne riječi: melanom, kasna metastaza, supraklavikularna regija, disekcija vrata
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